Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13489680 | 0.88 | CTSK (0.43) | KMT2AHSD17B10CTSKALDH1A1HTT | |
| SCHEMBL15764475 | 0.87 | TSHR (0.40) | KMT2AHSD17B10CTSKALDH1A1HTT | |
| SCHEMBL13489685 | 0.86 | HSD17B10 (0.43) | KMT2AHSD17B10CTSKALDH1A1HTT | |
| SCHEMBL13489726 | 0.82 | MEN1 (0.43) | KMT2AHSD17B10ALDH1A1HTTMEN1 | |
| SCHEMBL15762010 | 0.78 | HSD17B10 (0.40) | KMT2AHSD17B10ALDH1A1HTTMEN1 | |
| SCHEMBL8869239 | 0.78 | ALDH1A1 (0.40) | KMT2AHSD17B10ALDH1A1HTTMEN1 | |
| SCHEMBL9225777 | 0.78 | ALDH1A1 (0.40) | KMT2AHSD17B10ALDH1A1HTTMEN1 | |
| SCHEMBL8869251 | 0.78 | ALDH1A1 (0.40) | KMT2AHSD17B10ALDH1A1HTTMEN1 | |
| SCHEMBL15762030 | 0.76 | AAK1 (0.34) | KMT2AHSD17B10CTSKALDH1A1HTT | |
| SCHEMBL24595387 | 0.75 | HTT (0.47) | KMT2AHSD17B10CTSKALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048587-A1 | CYSTEINE AND CYSTINE BIOISOSTERES TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048587-A1 | CYSTEINE AND CYSTINE BIOISOSTERES TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | CTH, CBS, SLC7A11 | KMT2A 1850/4885HSD17B10 1403/4885CTSK 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.